Home > Quotes > SNTA

Synta Pharmaceuticals Corp. Common Stock Quote & Summary Data

Get SNTA Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading SNTA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SNTA Pre-Market
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Synta Pharmaceuticals Corp. Common Stock Intraday Chart

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 0.44 $ 2.65
Low $ 0.391 $ 0.15

The current last sale of $0.4125 is 175.00% Higher thanthe 52 week low.

P/E Ratio

Company Description (as filed with the SEC)

Synta Pharmaceuticals Corp. is a company that has been historically focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. In October 2015, we announced the decision to terminate for futility the Phase 3 GALAXY-2 trial of our novel heat shock protein 90 (Hsp90) inhibitor, ganetespib, and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the study's Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel was unlikely to demonstrate a statistically significant improvement in overall survival, the primary endpoint of the study, compared to docetaxel alone.  ... More ...  

Risk Grade

Where does SNTA fit in the risk graph?

Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?